Danuglipron
PF-06882961
An orally administered non-peptide GLP-1 receptor agonist studied in randomized trials for type 2 diabetes and weight management. Not FDA approved.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Half-life
Not established in a public source. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Not approved for human use; no public label defines handling.
References
- PubChem compound record
- Nat Med 2021: phase 1 multiple ascending-dose study in type 2 diabetes
- Metabolism 2023: review of oral small-molecule GLP-1 receptor agonists
Read the source
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.